In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the preceding trading day.

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...

After revenues flattened in the first three months of the year, in the second quarter Gilead saw its total sales fall 6%, largely down to shrinking revenues from its HCV portfolio. Sales shrunk in ...

The HIV and hepatitis C drugmaker's shares have seen an increase ... The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings per share ...

There has been a lot of discussion about the high price of Gilead's Hepatitis C drug Sovaldi, and a variety of strong opinions expressed. But are agencies around the world asking the right ...

New leadership at Seattle-area companies including Starbucks, Avanade, Tune Therapeutics, Umoja Biopharma, Siteimprove and ...

Leading epigenome company Tune Therapeutics is proud to announce that veteran drug-development executive John McHutchison AO, ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.

Vivani Medical Cofounder and CEO Adam Mendelsohn, Ph.D. discusses the company’s first application of the NanoPortal, ...